Microvast Holdings announces departure of chief financial officer
Investing.com - Iradimed Co (NASDAQ: IRMD) reported first quarter EPS of $0.42, $0.01 better than the analyst estimate of $0.41. Revenue for the quarter came in at $19.5M versus the consensus estimate of $19.13M.
Guidance
Iradimed Co sees Q2 2025 EPS of $0.41-$0.44 versus the analyst consensus of $0.43.
Iradimed Co sees Q2 2025 revenue of $19.70M-$19.90M versus the analyst consensus of $19.81M.
Iradimed Co sees FY 2025 EPS of $1.71-$1.81 versus the analyst consensus of $1.75.
Iradimed Co sees FY 2025 revenue of $78.00M-$82.00M versus the analyst consensus of $79.41M.
Iradimed Co’s stock price closed at $53.47. It is down -14.68% in the last 3 months and up 22.67% in the last 12 months.
Iradimed Co saw 1 positive EPS revisions and 1 negative EPS revisions in the last 90 days. See Iradimed Co’s stock price’s past reactions to earnings here.
According to InvestingPro, Iradimed Co’s Financial Health score is "great performance".
Check out Iradimed Co’s recent earnings performance, and Iradimed Co’s financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar